Costs and cost-effectiveness of Eptifibatide in the treatment of coronary ischemic syndromes. An analysis based on the PURSUIT study;Kosten und kosteneffektivität von eptifibatid in der behandlung des akuten koronarsyndroms. Eine analyse auf basis der PURSUIT-studie

Zeitschrift fur Kardiologie

Volumn 92, Issue 3, 2003, Pages 236-244

  Szucs, Thomas D ^a   Schwenkglenks, M ^a   Berger, K ^a   Karsch, K ^a  

^a Hirslanden Research   (Switzerland)

Author keywords

Coronary revascularization; Costs; Economic evaluation; Eptifibatide; Germany; Unstable angina pectoris

Indexed keywords

EPTIFIBATIDE; HEPARIN;

ARTICLE; CALCULATION; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; GERMANY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; MONEY; REIMBURSEMENT;

ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; COHORT STUDIES; CONFIDENCE INTERVALS; CORONARY ARTERY BYPASS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FIBRINOLYTIC AGENTS; HEPARIN; HOSPITALIZATION; HUMANS; MULTICENTER STUDIES; MYOCARDIAL INFARCTION; PEPTIDES; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS;

EID: 0037354237     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00392-003-0908-5     Document Type: Article

References (36)

1. Aristides M, Gliksman M, Rajan N, Davey P (1998) Effectiveness and cost-effectiveness of single bolus treatment of abciximab (Reo Pro) in preventing restenosis following percutaneous coronary angioplasty in high risk patients. Heart 79:12-17
2. Beck JR, Kassirer JP, Pauker SG et al (1982) A convenient approximation of life expectancy - The DEALE. II. Use in medical decision-maKonfidenzintervallng. Am J Med 73:889-897
3. Beck JR, Kassirer JP, Pauker SG et al (1982) A convenient approximation of life expectancy - the DEALE. I. Validation of the method. Am J Med 73:883-888
4. Berger K, Szucs T, Klose G (1997) Die Wirtschaftlichkeit von Arzneimitteltherapien: Eine sozioökonomische Analyse der CSE-Hemmung bei KHK-Patienten. Med Klin 92:363-369
5. Boden WE, O'Rourke RA, Crawford MH, Blaustein AS, Deedwania PC, Zoble RG, Wexler LF, Kleiger RE, Pepine CJ, Ferry DR, Chow BK, Lavori PW (1998) Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med 338:1785-1792
6. Cannon CP, Weintraub WS, Demopoulos LA et al (2001) TACTICS-Thrombolysis in Myocardial Infarction (TIMI) 18. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the GP IIb/III a inhibitor tirofiban. N Engl J Med 344:1879-1887
7. Das Bundesministerium für Gesundheit (Hrsg) (1999) Daten des Gesundheitswesens. Ausgabe 1999. Nomos, Baden-Baden
8. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction (1994) Results of the TIMI-IIIB Trial. Thrombolysis in Myocardial Ischemia. Circulation 89:1545-1556
9. Evans C (1997) The use of consensus methods and expert panels in pharmacoeconomic studies. Pharmaco Economics 12:121-129
10. Harrington RA (1997) Design and methodology of the PURSUIT trial: evaluating Eptifibatid for acute ischemic syndromes. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. Am J Cardiol 80:34B-38B
11. Mark DB, Harrington RA, Lincoff AM et al (2000) Cost-effectiveness of platelet glycoprotein IIb/II a inhibition with eptifibatide in patients with Non-ST-Elevation acute coronary syndromes. Circulation 101:366-371
12. Mark DB, Cowper PA, Berkowitz SD, Davidson-Ray L, DeLong ER, Turpie AGG, Califf RM, Weatherley B, Cohen M (1998) Economic assessment of low-molecular weight heparin (Enoxaparin) versus unfractionated heparin in acute coronary syndrome patients. Results from the ESSENCE randomized trial. Circulation 97:1702-1707
13. Mark DB, Talley JD, Topol EJ et al (1996) Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. Circulation 94:629-635
14. McElwee NE, Johnson ER (1997) Potential economic impact of glycoprotein IIb/IIIa inhibitors in improving outcomes of patients with acute ischemic coronary syndromes. Am J Cardiol 80:39B-43B
15. McFalls EO (1994) Cost-effectiveness of TIMI IIIB strategies. Circulation 90:2569
16. Nygard O, Nordrehaug JE, Refsum H et al (1997) Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 337:230-236
17. Obermann K, Graf v d Schulenburg JM, Mautner GC (1997) Ökonomische Analyse der Sekundärprävention der koronaren Herzkrankheit mit Simvastatin (Zocor®) in Deutschland. Med Klin 92:686-694
18. Pflegekostentarif des Universitätsklinikums Tübingen, Stand 1.4. 1998
19. Platelet IIb/IIIa Antagonism for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network (1998) International, randomized, controlled trial of lamifiban, heparin, or both in unstable angina. Circulation 97:2386-2395
20. The PURSUIT Trial Investigators (1998) Inhibition of platelet glycoprotein IIb/IIIa with Eptifibatid in patients with acute coronary syndromes. N Engl J Med 339:436-443
21. Ronner E, Dykun Y, van den Brand MJ, van der Wieken LR, Simoons ML (1998) Platelet glycoprotein IIb/IIIa receptor antagonists. An asset for treatment of unstable coronary syndromes and coronary intervention. Eur Heart J 19:1608-1616
22. Ruckdäschel S, Berger K, Szucs T (1996) Koronare Herzkrankheit - ein sozioökonomisches Problem? Münch Med Wschr 138:404-408
23. Statistisches Bundesamt (Hrsg) (1998) Statistisches Jahrbuch für die Bundesrepublik Deutschland, Gabler, Wiesbaden
24. Steg PG, Himbert D, Seknadji P (1997) Revascularisation of patients with unstable coronary artery disease: The case for early intervention. Am J Cardiol 80:45E-50E
25. Stone PH, Thompson B, Anderson HV, Kronenberg MW, Gibson RS, Rogers WJ, Diver-DJ, Theroux P, Warnica JW, Nasmith JB, Kells C, Kleiman N, McCabe CH, Schactman M, Knatterud GL, Braunwald E (1996) Influence of race, sex, and age on management of unstable angina and non-Q-wave myocardial infarction: The TIMI III registry. JAMA 275:1104-1112
26. Szucs T, Berger K, Schulte-Hillen J, Kleber FX (1996) Die Wirtschaftlichkeit von Captopril nach Myokardinfarkt. Med Klin 91:112-118
27. Szucs TD, Meyer BJ, Kiowski W (1999) Economic assessment of tirofiban in the management of acute coronary syndromes in the hospital setting: an analysis based on the PRISM PLUS trial. Eur Heart J 20:1253-1260
28. Szucs TD (1997) Pharmacoeconomics of angiotensin converting enzyme inhibitors in heart failure. Am J Hypertens 10:272S-279S
29. Tcheng JE (1996) Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am J Cardiol 78:35-40
30. Tengs TO, Adams ME, PlisKonfidenzintervalln JS et al (1995) Five hundred life-saving interventions and their cost-effectiveness. Risk analysis 15:1-33
31. The EPILOG Investigators (1997) Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 336:1689-1696
32. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators (1998) A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 338:1498-1505
33. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM PLUS) Study Investigators (1998) Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave-myocardial infarction. N Engl J Med 338:1488-1497
34. The RESTORE Investigators (1997) Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 96:1445-1453
35. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JF, Worley S, Ivanhoe R, George BS, Fintel D, Weston M et al (1994) Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 343:881-886
36. Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E for the FRISC II Investigators (2000) Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. Lancet 356:9-16